返回 
加入收藏
奈达铂与顺铂治疗晚期或复发性鳞状细胞非小细胞肺癌的成本-效果分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 奈达铂与顺铂治疗晚期或复发性鳞状细胞非小细胞肺癌的成本-效果分析 |
| TITLE： | Cost-effectiveness Analysis of Nedaplatin and Cisplatin in the Treatment of Advanced or Recurrent Squamous Cell NSCLC |
| 摘要： | 目的：为临床选择更具经济性的晚期或复发性鳞状细胞非小细胞肺癌（NSCLC）一线治疗方案、降低患者费用负担提供参考。方法：基于已发表的一项高质量的Ⅲ期临床随机对照试验，根据疾病发展过程建立Markov模型，将鳞状细胞NSCLC患者的疾病发展过程归为无进展生存状态、疾病进展状态和死亡状态，结合我院的治疗成本数据，对含奈达铂的ND方案与含顺铂的CD方案进行成本-效果分析，并采用单因素敏感度分析和概率敏感度分析对结果的不确定性进行评价。结果：根据Markov模型分析结果，ND方案的成本-效果比为54995.58元/质量调整生命年（QALYs），CD方案为50274.36元/QALYs，ND方案相对于CD方案的增量成本-效果比为86327.27元/QALYs，低于我国居民的意愿支付阈值（193932.00元/QALYs）。单因素敏感性分析结果提示，两组患者的无进展生存期对成本-效果分析结果的影响最大；概率敏感性分析结果提示，随着我国人均国内生产总值的增长，ND方案具有成本-效果的概率呈逐渐升高的趋势。结论：与CD方案相比，ND方案治疗晚期或复发性鳞状细胞NSCLC更具成本-效果优势。 |
| ABSTRACT： | OBJECTIVE：To provide reference for choosing a more economical first-line treatment for advanced or recurrent squamous cell NSCLC and reducting patients ’cost burden. METHODS ：Based on a published high-quality phase Ⅲ randomized clinical controlled trial ，Markov model was established according to the disease development process. The disease development process of patients with squamous cell NSCLC was divided into non-progressive free survival state ，disease progress state and death state. The cost-effectiveness analysis of ND regimen containing nedaplatin and CD regimen containing cisplatin was carried out on the basis of the treatment cost data of our hospital. The uncertainty of the results was evaluated with single factor sensitivity analysis and probability sensitivity analysis. RESULTS ：According to the results of analysis Markov model ，the cost-effectiveness in ND regimen was 54 995.58 yuan/QALYs，in CD regimen was 50 274.36 yuan/QALYs，and incremental cost-effectiveness ratio was 86 327.27 yuan/QALYs，which was lower than the willing payment threshold （193 932.00 yuan/QALYs）. The results of single factor sensitivity analysis showed that non-progressive free survival of patients accepted two regimens had the greatest influence on the cost-effectiveness analysis results. The probability sensitivity analysis showed that with the increase of per capita GDP in China ， the probability of cost-effectiveness of ND regimen increased gradually. CONCLUSIONS ：Compared with CD regimen ，ND regimen is more cost-effective in the treatment of advanced or recurrent squamous cell NSCLC. |
| 期刊： | 2020年第31卷第04期 |
| 作者： | 戴冰，占美，吴斌，吴逢波，杨甜，徐珽 |
| AUTHORS： | DAI Bing，ZHAN Mei，WU Bin，WU Fengbo ，YANG Tian，XU Ting |
| 关键字： | 奈达铂；顺铂；多西他赛；晚期；复发性；鳞状细胞非小细胞肺癌；成本-效果分析 |
| KEYWORDS： | Nedaplatin；Cisplatin；Docetaxel；Advanced；Recurrent；Squamous cell NSCLC；Cost-effectiveness analysis |
| 阅读数： | 483 次 |
| 本月下载数： | 12 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
